OncoMatch/Clinical Trials/NCT05954897

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Is NCT05954897 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC for hepatocellular carcinoma.

Phase 2RecruitingGuangdong Provincial People's HospitalNCT05954897Data as of May 2026

Treatment: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC — To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: liver transplantation

Previous liver transplantation

Lab requirements

Blood counts

Hb ≥ 90 g/dL; Neu ≥ 1.5 x 10^9/L; PLT ≥ 75 x 10^9/L; APTT ≤1.5 times the upper limit of normal

Kidney function

Cre ≤1.5 x upper limit of normal

Liver function

ALB ≥2.8 g/dL; TBIL ≤2 times the upper limit of normal; AST and ALT ≤ 3 times the upper limit of normal; Child-Pugh score ≤7

Adequate organ function, defined as: Hb ≥ 90 g/dL; Neu ≥ 1.5 x 10^9/L; PLT ≥ 75 x 10^9/L; ALB ≥2.8 g/dL; TBIL ≤2 times the upper limit of normal; AST and ALT ≤ 3 times the upper limit of normal; Cre ≤1.5 x upper limit of normal; APTT≤1.5 times the upper limit of normal. Child-Pugh score ≤7.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify